Diabetic Retinopathy Industry Is Estimated To Grow At A 6.5% CAGR In The Upcoming Period As The Scope And Its Applications Are Rising Enormously Across The Globe

The diabetic retinopathy market is expected to grow from US$ 7.78 billion in 2021 to US$ 12.04 billion by 2028; it is expected to grow at a CAGR of 6.5% from 2022 to 2028.

Diabetes is one of the most commonly diagnosed noncommunicable diseases. The increasing incidence of diabetes has been attributed to the growth of the diabetic retinopathymarket. Diabetic retinopathy is characterized by blurred vision and blindness as high sugar levels damage the retina.

Get PDF Sample Copy of this Report https://www.theinsightpartners.com/sample/TIPRE00004185/?utm_source=OpenPR&utm_medium=10396

Diabetic retinopathy is characterized by blurred vision and blindness as high sugar level damage the retina. According to the Centers for Disease Control and Prevention (CDC) data, diabetic retinopathy affects approximately one-third of the people with diabetes over the age of 40 years, and more than 4.2 million patients are currently living in the US with diabetic retinopathy. As a result, the market leaders are working on developing innovative treatments for diabetic retinopathy, and a wide variety of new related treatments are under investigation. For instance, in May 2019, Regeneron Pharmaceuticals, Inc. received FDA approval for EYLEA® (Aflibercept) Injection for the treatment of diabetic retinopathy.

Company Profiles-
Abbott Laboratories
Alimera Science
Allergan Plc
Ampio Pharmaceuticals
Bayer AG
F. Hoffmann-LA Roche
Novartis International AG
PFIZER
Regeneron Pharmaceuticals Inc
Valeant Pharmaceutical

Leading market players and manufacturers are studied to help give a brief idea about them in the report. The challenges faced by them and the reasons they are on that position are explained to help make a well informed decision. Competitive landscape of Diabetic Retinopathy market is given presenting detailed insights into the company profiles, developments, merges, acquisitions, economic status and best SWOT analysis.

Segments-

The global diabetic retinopathy market is segmented into type, treatment, and distribution. Based on type, the market is bifurcated into proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. Based on treatment, the market is segmented into anti-VEGF drug, steroid injection, laser surgeries, and vitrectomy

Based on distribution channel, the market Is segmented into retail pharmacies, hospital pharmacies, and others.

Enquire Before Buying https://www.theinsightpartners.com/inquiry/TIPRE00004185/?utm_source=OpenPR&utm_medium=10396

Contact Us:

If you have any queries about this report or if you would like further information, please

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, and Chemicals

This release was published on openPR.